Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03555825 · ClinicalTrials.gov registry record · Phase 3

Burke-Hocoma Efficiency Study

A Phase 3 study of Hemiparesis and Hemiplegia, sponsored by Burke Medical Research Institute.

Completed
Registry status
Phase 3
Development phase
47
Enrollment target
1
Study location

NCT03555825 is a Phase 3 study of Hemiparesis and Hemiplegia that has completed, run by Burke Medical Research Institute. The registered enrollment target is 47 participants, below the 58-participant average among 22 other Hemiparesis trials with a reported enrollment target (19% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03555825, a Phase 3 study of Hemiparesis and Hemiplegia, has completed, sponsored by Burke Medical Research Institute.

COMPLETED
Registry status
Phase 3
Development phase
47 participants
Enrollment target
1
Study location

Study Summary

The ArmeoSpring device is an exoskeleton (3 joints and 6 degrees of freedom) with integrated springs. The investigators hypothesize that 3 days of training for 6 weeks with the Hocoma Armeo Spring device will be efficient and more effective than one on one ArmeoSpring therapy.

Conditions Studied

Interventions

  • DEVICE Hocoma ArmeoSpring

Study Locations (1)

New York

  • Burke Medical Research Institute - White Plains

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2016-05-01
Est. Completion 2020-12
Phase Phase 3

Sponsor

Burke Medical Research Institute

11 total trials

What the Registry Record Tells You About NCT03555825

The ClinicalTrials.gov registry entry for NCT03555825 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 58-participant average among 22 other Hemiparesis trials with a reported enrollment target (19% lower). The listed sponsor is Burke Medical Research Institute, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hemiparesis appearing as the primary indexed condition, and to 1 intervention - of which Hocoma ArmeoSpring is the first listed.

NCT03555825 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03555825 about?

NCT03555825 is a clinical study titled "Burke-Hocoma Efficiency Study". The ArmeoSpring device is an exoskeleton (3 joints and 6 degrees of freedom) with integrated springs. The investigators hypothesize that 3 days of training for 6 weeks with the Hocoma Armeo Spring device will be efficient and more effective than one on one ArmeoSpring therapy.

What is the current status of trial NCT03555825?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 47 participants. The study started on 2016-05-01. Estimated completion is 2020-12.

What conditions does trial NCT03555825 study?

This clinical trial studies the following conditions: Hemiparesis, Hemiplegia.

What interventions are being tested in trial NCT03555825?

The interventions under investigation include: Hocoma ArmeoSpring (DEVICE).

Who is sponsoring clinical trial NCT03555825?

This trial is sponsored by Burke Medical Research Institute, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03555825 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hemiparesis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.